Arrowhead Research Corp Increases Ownership of Calando Pharmaceuticals

Arrowhead Research Corporation (NASDAQ:ARWR) (“the Company”) today announced that it has increased its ownership of majority owned subsidiary Calando Pharmaceuticals through the exchange of Calando Series A Preferred Stock for Arrowhead warrants.

This exchange follows recent milestones achieved by Calando, including several notable first accomplishments in RNAi technology. These include proof of the first definitive systemic siRNA delivery and first to show RNAi mediated knockdown of target mRNA and protein in humans.

.“We see significant value in Calando and, therefore, are interested in maximizing our ownership position in the company,” said Christopher Anzalone, Arrowhead’s CEO. “Acquisition of this majority block of Calando Series A stock is a good transaction for us because it increases our ownership in Calando and enables us additional flexibility as we work to negotiate the right partnership or series of partnerships for Calando’s industry leading RNAi delivery platform and exciting therapeutic candidate, CALAA-01. Calando is making continued progress toward completing the phase 1 clinical trial of CALAA-01 and interfacing with potential strategic partners.”

Pursuant to the exchange agreement between Arrowhead and the Calando Series A holders, Arrowhead exchanged a warrant to purchase approximately 3.9 million shares of Arrowhead stock for Calando Series A Preferred Stock with a liquidation preference of approximately $3.9 million. The Calando preferred stock is convertible into 2.7 million shares of Calando common stock at the discretion of the holder. The warrants have an exercise price of $0.50 per share and are exercisable beginning March 17, 2011, with an expiration date of September 16, 2015.

Arrowhead Research Corporation () (NASDAQ:ARWR) is a nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is seeking to build value for shareholders through the progress of majority owned subsidiaries. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications and minority investments in two privately held nanobiotech companies.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Arrowhead Pharmaceutical. (2019, February 13). Arrowhead Research Corp Increases Ownership of Calando Pharmaceuticals. AZoNano. Retrieved on December 04, 2024 from https://www.azonano.com/news.aspx?newsID=19658.

  • MLA

    Arrowhead Pharmaceutical. "Arrowhead Research Corp Increases Ownership of Calando Pharmaceuticals". AZoNano. 04 December 2024. <https://www.azonano.com/news.aspx?newsID=19658>.

  • Chicago

    Arrowhead Pharmaceutical. "Arrowhead Research Corp Increases Ownership of Calando Pharmaceuticals". AZoNano. https://www.azonano.com/news.aspx?newsID=19658. (accessed December 04, 2024).

  • Harvard

    Arrowhead Pharmaceutical. 2019. Arrowhead Research Corp Increases Ownership of Calando Pharmaceuticals. AZoNano, viewed 04 December 2024, https://www.azonano.com/news.aspx?newsID=19658.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.